Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
Humacyte (Nasdaq: HUMA) will release third quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 AM Eastern Time to provide a corporate and financial update. The webcast will be accessible 15 minutes prior to the start time and a replay will be available on the company's investor website for at least 30 days.
Dial-in numbers are provided for U.S. and international investors and a conference ID is listed for access. The event covers the company’s corporate and financial update and is scheduled to coincide with the quarterly results release.
Humacyte (Nasdaq: HUMA) pubblicherà i risultati finanziari del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025 il mercoledì 12 novembre 2025. La gestione terrà un webcast e una conference call alle 8:00 AM Eastern Time per fornire un aggiornamento aziendale e finanziario. Il webcast sarà accessibile 15 minuti prima dell'inizio e una riproduzione sarà disponibile sul sito degli investitori dell'azienda per almeno 30 giorni.
Sono forniti numeri di dial-in per investitori statunitensi e internazionali, e un ID conferenza è elencato per l'accesso. L'evento riguarda l'aggiornamento aziendale e finanziario ed è programmato per coincidere con la pubblicazione dei risultati trimestrali.
Humacyte (Nasdaq: HUMA) publicará los resultados financieros del tercer trimestre de 2025 para el periodo terminado el 30 de septiembre de 2025 el miércoles 12 de noviembre de 2025. La dirección realizará un webcast y conferencia telefónica a las 8:00 AM hora del Este para proporcionar una actualización corporativa y financiera. El webcast estará accesible 15 minutos antes del inicio y una reproducción estará disponible en el sitio web de inversores de la empresa durante al menos 30 días.
Se proporcionan números de marcación para inversionistas de EE. UU. y a nivel internacional y se indica un ID de conferencia para acceder. El evento cubre la actualización corporativa y financiera de la empresa y está programado para coincidir con la publicación de resultados trimestrales.
휴메이시트(Humacyte, Nasdaq: HUMA)는 2025년 9월 30일로 종료되는 기간에 대한 2025년 3분기 재무실적을 2025년 11월 12일 수요일에 발표합니다. 경영진은 웹캐스트 및 컨퍼런스 콜을 동부 표준시 오전 8시에 개최하여 기업 및 재무 업데이트를 제공합니다. 웹캐스트는 시작 15분 전에 접근 가능하며 회사의 투자자 웹사이트에서 최소 30일간 재생을 이용할 수 있습니다.
미국 및 국제 투자자를 위한 다이얼 인 번호가 제공되며 접근을 위한 컨퍼런스 ID가 명시되어 있습니다. 이 행사는 회사의 기업 및 재무 업데이트를 다루며 분기 실적 발표와 일치하도록 예정되어 있습니다.
Humacyte (NASDAQ : HUMA) publiera les résultats financiers du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025 le mercredi 12 novembre 2025. La direction organisera un webcast et une conférence téléphonique à 8h00, heure de l'Est pour fournir une mise à jour d'entreprise et financière. Le webcast sera accessible 15 minutes avant le début et une rediffusion sera disponible sur le site des investisseurs de l'entreprise pendant au moins 30 jours.
Des numéros de dial-in sont fournis pour les investisseurs américains et internationaux et un identifiant de conférence est indiqué pour l'accès. L'événement couvre la mise à jour d'entreprise et financière et est prévu pour coïncider avec la publication des résultats trimestriels.
Humacyte (Nasdaq: HUMA) wird die Finanzergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025 am Mittwoch, den 12. November 2025, veröffentlichen. Das Management wird einen Webcast und Conference Call um 8:00 Uhr Ostzeit durchführen, um ein Unternehmens- und Finanzupdate bereitzustellen. Der Webcast ist 15 Minuten vor dem Start zugänglich, und eine Wiedergabe wird auf der Investorenseite des Unternehmens für mindestens 30 Tage verfügbar sein.
Dial-in-Nummern werden für US-amerikanische und internationale Investoren bereitgestellt und eine Conference-ID wird für den Zugriff aufgeführt. Die Veranstaltung behandelt das Unternehmens- und Finanzupdate und soll mit der Veröffentlichung der Quartalsergebnisse zusammenfallen.
Humacyte (ناسداك: HUMA) ستصدر نتائجها المالية للربع الثالث من عام 2025 للفترة المنتهية في 30 سبتمبر 2025 يوم الأربعاء 12 نوفمبر 2025. ستقدّم الإدارة ندوة بث حيّة واتصالاً هاتفيّاً للمؤتمر في الساعة 8:00 صباحاً بتوقيت الساحل الشرقي لتقديم تحديثٍ شركة ومالي. سيكون البث المباشر متاحاً قبل 15 دقيقة من البداية، وسيكون بإمكان المستخدمين إعادة مشاهدة ذلك على موقع المستثمرين للشركة لمدة لا تقل عن 30 يوماً.
يتم توفير أرقام الاتصال للمستثمرين الأمريكيين والدوليين، ولائحة تعريف المؤتمر مذكورة للوصول. تغطي الفعالية تحديث الشركة والماليات ومن المقرر أن تتزامن مع إصدار نتائج الربع.
- None.
- None.
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
| Title: | Humacyte Third Quarter 2025 Financial Results and Corporate Update |
| Date: | November 12, 2025 |
| Time: | 8:00 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13756236 (Conference ID) |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) report Q3 2025 results?
What time is the Humacyte (HUMA) Q3 2025 webcast and call?
How can investors join the Humacyte (HUMA) conference call?
When will the Humacyte (HUMA) webcast be available to join?
Will Humacyte (HUMA) provide a replay of the Q3 2025 webcast?
Where can investors find materials from the Humacyte (HUMA) November 12, 2025 presentation?
